Big Buck Brewery Steakhouse (fka BBUCQ) : Holding up here. Would live a $1 pop!

Play Episode

3min

Proactive - Interviews for investors

Hillcrest launches ZVS technology evaluation with global Tier 1 automotive supplier

Hillcrest Energy Technologies CEO Don Currie joined Steve Darling from Proactive to announce the launch of a technology evaluation project with a global Tier 1 automotive supplier. The project’s initial phase will assess the potential benefits of Hillcrest’s Zero Voltage Switching (ZVS) technology in next-generation inverter applications for electric vehicles. If this phase is successful and both parties agree to proceed, subsequent phases will focus on the integration and validation of ZVS technology within the supplier’s inverter platform. Currie explained that Tier 1 automotive suppliers provide fully assembled components and systems to major automakers. This particular supplier, consistently ranked among the top 15 largest by revenue, is a global leader specializing in critical EV components like inverters. With a strong presence in the industry, the supplier plays a crucial role in advancing electric vehicle technology for manufacturers worldwide. The evaluation phase will involve a series of technical assessments aimed at eliminating switching losses and improving electromagnetic compatibility (EMC) performance. The supplier will analyze efficiency, performance, and potential advantages of Hillcrest’s ZVS technology within its inverter architecture. The findings from this evaluation will determine potential next steps for further collaboration and integration. This project represents a key opportunity for Hillcrest to demonstrate the value of its ZVS technology, with the shared objective of enhancing EV inverter performance and delivering significant benefits to automotive customers. #proactiveinvestors #hillcrestenergytechnologiesltd #cse #heat #ptcqb #hlrtf

Proactive - Interviews for investors

Data security: archTIS lands key licensing deal

archTIS Ltd CEO and Managing Director Daniel Lai talked with Proactive about a newly signed $390,000 licensing agreement with a major Japanese multinational. The deal builds on archTIS’s acquisition of Direktiv and its integration of advanced cybersecurity technology into its Trusted Data Integration platform. Lai explained that the licensing agreement enables the Japanese company—an asset services provider with operations valued at $12.5 billion—to introduce new data-centric security services into the Japanese market. “This is just another example of that occurring, which is really exciting for the company,” Lai said, referring to archTIS’s broader international expansion strategy. He noted that the company had always planned to replicate its success with the Australian Department of Defence and local defence industrial base in overseas markets, particularly those facing geopolitical pressures. Lai also highlighted progress in the US and Europe, where trials were recently completed with a large US department and NATO in the UK. Looking ahead, he remained “quietly optimistic” about meeting financial targets by June 30 and delivering further material updates to the market. He acknowledged market timing and election cycles as influencing deal flow, but said government and intelligence agency engagement continues to build momentum. Visit Proactive's YouTube channel for more interviews and updates. Don’t forget to like the video, subscribe, and turn on notifications for future content. #archTIS #Cybersecurity #DataSecurity #LicensingDeal #JapaneseMarket #QuadAlliance #TrustedDataIntegration #GlobalExpansion #DefenseTechnology #ProactiveInvestors

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Followers	2162
Posts	166955
Boards Moderated	10
Alias Born	09/08/2010

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free